PURPOSE: In vitro transcription/translation (IVTT) systems are widely used in proteomics. For clinical applications, mammalian systems are preferred for protein folding and activity; however, the level of protein obtained is low. A new system extracted from human cells (1-Step Human Coupled IVT (HCIVT)) has the potential to overcome this problem and deliver high yields of protein expressed in a human milieu. EXPERIMENTAL DESIGN: Western blots and self-assembled protein microarrays were used to test the efficiency of protein synthesis by HCIVT compared to rabbit reticulocyte lysate (RRL). The arrays were also used to measure the immune response obtained from serum of patients exposed to pathogens or vaccine. RESULTS: HCIVT performed better than RRL in all experiments. The yield of protein synthesized in HCIVT is more than ten times higher than RRL, in both Western blot and protein microarrays. Moreover, HCIVT showed a robust lot-to-lot reproducibility. In immune assays, the signals of many antigens were detected only in HCIVT-expressed arrays, mainly due to the reduction in the background signal and the increased levels of protein on the array. CONCLUSION AND CLINICAL RELEVANCE: HCIVT is a robust in vitro transcription and translation system that yields high levels of protein produced in a human milieu. It can be used in applications where protein expression in a mammalian system and high yields are needed. The increased immunogenic response of HCIVT-expressed proteins will be critical for biomarker discovery in many diseases, including cancer.
PURPOSE: In vitro transcription/translation (IVTT) systems are widely used in proteomics. For clinical applications, mammalian systems are preferred for protein folding and activity; however, the level of protein obtained is low. A new system extracted from human cells (1-Step Human Coupled IVT (HCIVT)) has the potential to overcome this problem and deliver high yields of protein expressed in a human milieu. EXPERIMENTAL DESIGN: Western blots and self-assembled protein microarrays were used to test the efficiency of protein synthesis by HCIVT compared to rabbit reticulocyte lysate (RRL). The arrays were also used to measure the immune response obtained from serum of patients exposed to pathogens or vaccine. RESULTS:HCIVT performed better than RRL in all experiments. The yield of protein synthesized in HCIVT is more than ten times higher than RRL, in both Western blot and protein microarrays. Moreover, HCIVT showed a robust lot-to-lot reproducibility. In immune assays, the signals of many antigens were detected only in HCIVT-expressed arrays, mainly due to the reduction in the background signal and the increased levels of protein on the array. CONCLUSION AND CLINICAL RELEVANCE: HCIVT is a robust in vitro transcription and translation system that yields high levels of protein produced in a human milieu. It can be used in applications where protein expression in a mammalian system and high yields are needed. The increased immunogenic response of HCIVT-expressed proteins will be critical for biomarker discovery in many diseases, including cancer.
Authors: Karen S Anderson; Sahar Sibani; Garrick Wallstrom; Ji Qiu; Eliseo A Mendoza; Jacob Raphael; Eugenie Hainsworth; Wagner R Montor; Jessica Wong; Jin G Park; Naa Lokko; Tanya Logvinenko; Niroshan Ramachandran; Andrew K Godwin; Jeffrey Marks; Paul Engstrom; Joshua Labaer Journal: J Proteome Res Date: 2010-11-23 Impact factor: 4.466
Authors: Bing Z Carter; Yi Hua Qiu; Nianxiang Zhang; Kevin R Coombes; Duncan H Mak; Deborah A Thomas; Farhad Ravandi; Hagop M Kantarjian; Erich Koller; Michael Andreeff; Steven M Kornblau Journal: Blood Date: 2010-11-01 Impact factor: 22.113
Authors: H Zhu; M Bilgin; R Bangham; D Hall; A Casamayor; P Bertone; N Lan; R Jansen; S Bidlingmaier; T Houfek; T Mitchell; P Miller; R A Dean; M Gerstein; M Snyder Journal: Science Date: 2001-07-26 Impact factor: 47.728
Authors: Shajo Kunnath-Velayudhan; Hugh Salamon; Hui-Yun Wang; Amy L Davidow; Douglas M Molina; Vu T Huynh; Daniela M Cirillo; Gerd Michel; Elizabeth A Talbot; Mark D Perkins; Philip L Felgner; Xiaowu Liang; Maria L Gennaro Journal: Proc Natl Acad Sci U S A Date: 2010-07-28 Impact factor: 11.205
Authors: Niroshan Ramachandran; Eugenie Hainsworth; Bhupinder Bhullar; Samuel Eisenstein; Benjamin Rosen; Albert Y Lau; Johannes C Walter; Joshua LaBaer Journal: Science Date: 2004-07-02 Impact factor: 47.728
Authors: Sorina C Popescu; George V Popescu; Shawn Bachan; Zimei Zhang; Montrell Seay; Mark Gerstein; Michael Snyder; S P Dinesh-Kumar Journal: Proc Natl Acad Sci U S A Date: 2007-02-23 Impact factor: 11.205
Authors: Xiaobo Yu; Andrew R Woolery; Phi Luong; Yi Heng Hao; Markus Grammel; Nathan Westcott; Jin Park; Jie Wang; Xiaofang Bian; Gokhan Demirkan; Howard C Hang; Kim Orth; Joshua LaBaer Journal: Mol Cell Proteomics Date: 2014-07-29 Impact factor: 5.911
Authors: Jie Wang; Jonine D Figueroa; Garrick Wallstrom; Kristi Barker; Jin G Park; Gokhan Demirkan; Jolanta Lissowska; Karen S Anderson; Ji Qiu; Joshua LaBaer Journal: Cancer Epidemiol Biomarkers Prev Date: 2015-06-12 Impact factor: 4.254
Authors: Karen S Anderson; Jennifer E Gerber; Gypsyamber D'Souza; Sara I Pai; Julia N Cheng; Rizwan Alam; Sailaja Kesiraju; Diego Chowell; Neil D Gross; Robert Haddad; Maura L Gillison; Marshall Posner Journal: Oral Oncol Date: 2015-06-18 Impact factor: 5.337
Authors: Kristina R Dahlstrom; Karen S Anderson; Matthew S Field; Diego Chowell; Jing Ning; Nan Li; Qingyi Wei; Guojun Li; Erich M Sturgis Journal: Cancer Date: 2017-09-12 Impact factor: 6.860